Bayer's $2.2 Billion Ohio Campus Won't Produce a Single Pill Until 2031 — and the Market Has Noticed

Bayer commits $2.2B to an Ohio pharma campus, but first output isn't due until 2031 as glyphosate settlement approval and patent losses weigh.

Bayer shares closed Wednesday at EUR 44.07, down 2.1%, as investors weighed two very different timelines: a decade-long US manufacturing buildout and a legal calendar that refuses to move any faster.

The Leverkusen-based group has committed USD 2.2 billion to a modular pharmaceutical campus in New Albany, Ohio — a project that CEO Bill Anderson says will break ground by mid-2027, with the construction procurement approach finalized early in that same year. A training center in Ohio is slated to open in summer 2027 to prepare workers for highly automated bioproduction.

Yet the first active-ingredient module is not scheduled to come online until 2031. The finished-drugs unit follows in 2034. Between now and then, Bayer must plug a widening revenue hole left by expiring patents with nothing new from Ohio.

A Decade-Long Gap Between Promise and Production

The arithmetic is unforgiving. Xarelto, once a dependable earner, saw its revenue slump 31.6% on an adjusted basis in 2025. Nubeqa, the prostate cancer drug positioned as a key growth engine, climbed 62.4% in currency-adjusted terms to EUR 2.39 billion — impressive, but not yet large enough to offset the decline alone.

North America's share of Bayer's pharmaceutical revenue has nonetheless swelled from roughly 20% in 2018 and 2019 to about 35% today, according to Sebastian Guth. That shift underscores why management is pressing ahead: the US is the world's largest healthcare market, and Bayer's pharma sales there rose 19.7% in 2025 on a currency- and portfolio-adjusted basis to EUR 5.84 billion.

Over the past five years, Bayer has already spent more than USD 7 billion on US pharmaceutical research, development and production. The Ohio campus is designed to protect that position against regulatory and trade-policy headwinds — and to manufacture treatments for oncology, cardiovascular and kidney diseases using digital and automated processes.

JobsOhio, the state's economic development agency, is contributing up to USD 30 million.

Legal Clouds Refuse to Lift

While the Ohio blueprint advances, Bayer's courtroom exposure remains the more immediate concern for shareholders. The company is still awaiting judicial approval of a USD 7.25 billion US settlement covering outstanding glyphosate claims. That unresolved overhang has made the stock acutely sensitive to negative sector news.

Regulatory pressure in Europe compounds the problem. At the end of September, EU member states rejected indefinite approvals for plant protection products, meaning glyphosate remains subject to fixed-term authorizations and recurring re-evaluations.

Against that backdrop, JPMorgan's Richard Vosser kept his "Overweight" rating and EUR 61 price target on October 1 but cautioned that early third-quarter expectations looked inflated — a view he tied primarily to timing-related softness in the agricultural division.

Pipeline Wins and Balance-Sheet Moves

Bayer has not stood still on other fronts. In September, the group placed two tranches of hybrid bonds totaling EUR 2 billion, with non-call periods of six and nine years, as part of efforts to optimize its financing structure.

Regulatory progress in the US offered some counterweight. The FDA granted Lynkuet (elinzanetant) a Priority Review for an additional indication — treating moderate-to-severe vasomotor symptoms in women undergoing endocrine therapy for hormone receptor-positive breast cancer. Separately, Bayer and subsidiary BlueRock Therapeutics received Orphan Drug designation from both the FDA and the European Medicines Agency in late September for the cell therapy candidate Lemiretprocel, aimed at primary photoreceptor diseases.

What the Chart Says — and What Comes Next

Technically, the stock's medium-term recovery hinges on holding its 200-day moving average at EUR 43.13. A decisive break below that level would risk extending the recent consolidation; defending it keeps the rebound narrative alive.

The more consequential test arrives November 3, 2026, when Bayer publishes its quarterly statement and detailed third-quarter results. Only then will investors get hard numbers on how deeply the agricultural slump has cut into earnings — and whether the Ohio bet, still years from producing anything, remains a credible bridge across the patent cliff.